BDX Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $5.9 billion, up 7% (3.9% organic growth).

Full Year Revenue: $21.8 billion, up 7.7% (2.9% organic growth).

Adjusted Diluted EPS: $3.96 in Q4 (3.9% growth), $14.40 for the full year (9.6% growth).

Adjusted Gross Margin: 54.2% in Q4, 54.7% for the full year.

Adjusted Operating Margin: 25.8% in Q4, 25% for the full year.

Shareholder Returns: $2.2 billion returned, including a $1 billion share buyback.

2Strategic Updates and Business Highlights

Transitioned to a new segment structure: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences.

Strong organic growth in BD Interventional (high single digits) and Advanced Patient Monitoring (double digits).

Continued investment in R&D, reallocating $50 million from corporate costs to fuel innovation in high-growth markets.

Initiated a $200 million cost-out program to address stranded corporate costs.

New Chief Revenue Officer role created to enhance commercial excellence and align sales teams with business units.

3Forward Guidance and Outlook

Fiscal 2026 Guidance: Low single-digit revenue growth expected, with adjusted diluted EPS projected between $14.75 and $15.05.

Anticipated headwinds include:

Alaris capital installations creating a 100 basis point growth headwind.

Mid-teen decline in China due to government procurement policies.

Continued reductions in vaccine demand impacting Pharm Systems revenue.

Q1 revenue expected to decline low single digits, with a stronger performance anticipated in Q2 and Q3.

4Bad News, Challenges, or Points of Concern

Notable declines in vaccine demand, which constitutes about 20% of Pharm Systems revenue, expected to drop by approximately 25%.

China market dynamics are challenging, with a projected mid-teen revenue decline.

The Alaris product line is expected to create a headwind to growth due to prior strong performance and ongoing remediation commitments.

The company is navigating transitory market dynamics that may impact performance in the short term.

5Notable Q&A Insights

Management emphasized a conservative approach to guidance, incorporating macroeconomic challenges and specific portfolio dynamics.

Confidence expressed in achieving mid-single-digit growth long-term, despite current headwinds.

Discussions on capital allocation highlighted a focus on share buybacks and investments in high-growth areas.

The new commercial strategy aims to enhance performance and leverage existing strengths, with expectations for benefits to materialize in the near term.

The leadership transition was acknowledged, with Chris DelOrefice moving to a new role, ensuring continuity in financial strategy. Overall, BD's Q4 2025 results reflect strong operational performance and strategic initiatives, although challenges in specific markets and segments present potential headwinds for the upcoming fiscal year.